Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Evaluation of pulmonary absorption using pharmacokinetic methods
Autore:
Derendorf, H; Hochhaus, G; Mollmann, H;
Indirizzi:
Univ Florida, Coll Pharm, Gainesville, FL 32610 USA Univ Florida Gainesville FL USA 32610 ll Pharm, Gainesville, FL 32610 USA
Titolo Testata:
JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG
, volume: 14, anno: 2001, supplemento:, 1
pagine: S9 - S17
SICI:
0894-2684(2001)14:<S9:EOPAUP>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
LUNG FOLLOWING INHALATION; METERED-DOSE INHALER; TRIAMCINOLONE ACETONIDE PHOSPHATE; FLUTICASONE PROPIONATE; RELATIVE BIOAVAILABILITY; GAMMA-SCINTIGRAPHY; HEALTHY-SUBJECTS; SPACER DEVICES; SEVERE ASTHMA; DEPOSITION;
Keywords:
lung; pharmacokinetics; therapy; inhalation;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
33
Recensione:
Indirizzi per estratti:
Indirizzo: Derendorf, H Univ Florida, Coll Pharm, 100494, Gainesville, FL 32610 USA Univ Florida 100494 Gainesville FL USA 32610 le, FL 32610 USA
Citazione:
H. Derendorf et al., "Evaluation of pulmonary absorption using pharmacokinetic methods", J AEROSOL M, 14, 2001, pp. S9-S17

Abstract

When assessing inhaled drug absorption, standard pharmacokinetic analyses cannot differentiate drug that reaches the systemic circulation from the lungs from that of the gut. Pulmonary absorption kinetics can be assessed fordrugs with negligible gastrointestinal absorption or for drugs that are eliminated via first-pass metabolism. For other drugs, pulmonary absorption kinetics can be studied by blocking gastrointestinal absorption with charcoal, or by studying absorption during the first 30 minutes post inhalation before appreciable oral absorption has occurred. Pharmacokinetic data generally agree well with pulmonary deposition data derived by measuring inhaled radiotracer-labelled drug using gamma -scintigraphy. Monitoring pulmonary and oral absorption also provides information on total systemic exposure and therefore safety. Furthermore, the duration of action of different inhaled drugs and the degree of pulmonary targeting can be obtained by determining the corticosteroid occupancy of lung and systemic glucocorticoid receptors. Pharmacokinetic data from healthy volunteers cannot be extrapolated to patients with asthma, as systemic exposure to inhaled drugs can be markedly less in patients than in healthy volunteers. This correlates with the observed differences in side effects in these two groups. Although pharmacokineticmethods do not provide information on regional deposition, they do generate data on systemic and pulmonary exposure, and so play a role in the development of delivery systems.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/01/20 alle ore 02:02:42